This work was aimed to develop a NIR analytical method for bilastine assay in powder mixtures for direct compression. In particular, the use of NIR instrumentation should allow to control the bilastine concentration and the whole blending process, assuring the achievement of a homogeneous blend. The commercial tablet formulation of bilastine was particularly suitable for this purpose, due to its simple composition (four excipients) and direct compression manufacturing process. Calibration and validation set were prepared according to a Placket-Burman experimental design and acquired with a miniaturized NIR in-line instrument (MicroNIR by Viavi SolutionInc.). Chemometric was applied to optimize information extraction from spectra, by subjecting them to aStandard Normal Variate (SNV) and a Savitzky-Golay second derivative pre-treatment. This spectra pre-treatment, combined with the most suitable wavelength interval (resulted between 1087 and 1217 nm),enabled to obtain a Partial Least Square (PLS) model with a good predictive ability. The selected model, tried on laboratory and production batches, provided in both cases good assay predictions. Results were confirmed by traditional HPLC drug content uniformity test on the final product.
Development of a Near Infrared Spectroscopy method for the in-line quantitative bilastine drug determination during pharmaceuticals powders blending / Diletta Biagi, Paolo Nencioni, Maurizio Valleri, Niccolò Calamassei, Paola Mura. - In: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. - ISSN 0731-7085. - ELETTRONICO. - 204:(2021), pp. 0-0. [10.1016/j.jpba.2021.114277]
Development of a Near Infrared Spectroscopy method for the in-line quantitative bilastine drug determination during pharmaceuticals powders blending
Diletta Biagi
Methodology
;Paola MuraWriting – Review & Editing
2021
Abstract
This work was aimed to develop a NIR analytical method for bilastine assay in powder mixtures for direct compression. In particular, the use of NIR instrumentation should allow to control the bilastine concentration and the whole blending process, assuring the achievement of a homogeneous blend. The commercial tablet formulation of bilastine was particularly suitable for this purpose, due to its simple composition (four excipients) and direct compression manufacturing process. Calibration and validation set were prepared according to a Placket-Burman experimental design and acquired with a miniaturized NIR in-line instrument (MicroNIR by Viavi SolutionInc.). Chemometric was applied to optimize information extraction from spectra, by subjecting them to aStandard Normal Variate (SNV) and a Savitzky-Golay second derivative pre-treatment. This spectra pre-treatment, combined with the most suitable wavelength interval (resulted between 1087 and 1217 nm),enabled to obtain a Partial Least Square (PLS) model with a good predictive ability. The selected model, tried on laboratory and production batches, provided in both cases good assay predictions. Results were confirmed by traditional HPLC drug content uniformity test on the final product.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bilastine NIR assay.pdf
Accesso chiuso
Descrizione: Articolo completo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
2.08 MB
Formato
Adobe PDF
|
2.08 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



